Saturday 17 October 2026 Export KPRX’s income statement to Excel — free account

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.

2.40 0.01 −0.41%

Follow KPRX

Alert me

Market cap: $10.7M
P/E: 0.0×
Fwd P/E: −1.2×
Dividend yield: —
F-score: n/a
Altman Z: −3.16
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 36.71%

Capital & Financial Ratios $m

Market Cap 10.66

Revenue 18.72

Net Income (10.99)

Free Cash Flow (8.61)

Net Debt (16.84)

Current Ratio 8.97

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.22)

P/S ratio 0.79

P/B ratio 0.88

Past 5Y EPS Growth —

This Y EPS Growth 36.74%

Next Y EPS Growth 49.10%

Next Y revenue growth (90.64%)

Next 5Y EPS Growth 28.62%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 24.17%

10-year low 10-year high

P/B against its own 10 years 43.24%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	27	17	17
Receivables	2	1	3	3
Inventory	—	—	—	—
Other	—	—	0	0
	5	30	22	21

	2023	2024	2025	Q'26
Payables	0	0	1	0
ST’ Debt	—	—	—	—
Other	—	1	—	—
	2	6	4	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	88.72%	113.23%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	10.23%	10.63%	12.23%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	16	0	—	—	16
’20	—	—	—	0	0
’19	3	—	—	—	3
’18	1	0	0	—	2
’17	0	0	0	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(3)	(4)	(1)	(2)	(10)
’24	14	(4)	1	(2)	9
’23	(3)	(1)	(3)	(3)	(10)
’22	(3)	(2)	(3)	(2)	(10)
’21	(3)	(3)	(2)	(3)	(11)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(3)	(4)	(1)	(2)	(10)
’24	14	(4)	1	(2)	9
’23	(3)	(1)	(3)	(3)	(10)
’22	(3)	(2)	(3)	(2)	(10)
’21	(3)	(3)	(2)	(3)	(11)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.58)	(0.34)	—	—	—
’25	(0.52)	(0.54)	0.01	(1.60)	(2.64)
’24	3.42	(0.53)	(0.81)	(1.04)	0.87
’23	(9.00)	(7.11)	(8.01)	0.20	(24.21)
’22	(97.21)	(1.65)	(54.27)	(9.53)	(166.97)
’21	(98.38)	(126.01)	(104.41)	(280.83)	(637.26)
’20	(154.81)	(136.81)	(158.42)	(87.74)	(637.26)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5,994.00	4,860.00	1,485.00	810.00	1,152.00	288.00	20.88	4.16	3.00	1.77	Analyst estimates 2026–2028 Powerpack
	High	27,540.00	21,060.00	7,236.00	4,640.40	3,668.40	2,826.00	511.20	76.64	8.98	4.18
People
People	Employees	11	17	11	10	14	14	12	12	12	13
	Revenue/emp, $m	0.06	0.02	0.15	0.27	0.00	0.00	0.00	0.00	1.34	0.00
Income, $m
Income, $m	Revenue	1	0	2	3	0	—	—	—	16	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	0.00	0.00	—	100.00	—
	EBT	(13)	(15)	(11)	(7)	(7)	(14)	(14)	(12)	6	(12)
	EBT margin, %	(1,993.64)	(3,572.98)	(649.04)	(260.66)	(56,609.09)	0.00	0.00	0.00	35.33	0.00
	Net income	(13)	(13)	(11)	(7)	(7)	(14)	(14)	(13)	4	(11)
	Depreciation	0	0	0	0	0	4	0	0	0	0
Per share, $
Per share, $	Revenue	418.31	156.73	250.38	305.23	0.95	0.00	0.00	0.00	4.14	0.00
	Earnings	(8,150.74)	(5,019.99)	(1,619.35)	(802.88)	(637.26)	(637.26)	(166.97)	(24.21)	0.93	(2.60)
	Cash flow	(5,258.25)	(2,487.88)	(1,643.11)	(926.57)	(571.66)	(398.34)	(128.27)	(17.76)	2.21	(2.39)
	Capex	(6.87)	(14.23)	(3.03)	0.00	(1.57)	(2.38)	0.08	0.00	0.00	(0.03)
	Free cash flow	(5,265.12)	(2,502.12)	(1,646.14)	(926.57)	(573.23)	(400.72)	(128.19)	(17.76)	2.21	(2.42)
	Book value	(205.87)	(741.12)	1,353.98	752.56	760.13	544.00	140.31	11.36	6.65	3.87
	Shares, m	0	0	0	0	0	0	0	1	4	4
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	—	1.51	—
	P/S	0.00	27.69	9.60	7.32	6.98	—	—	—	0.68	—
	P/B	0.00	0.00	1.85	4.79	2.33	—	—	—	0.50	—
	EV/Sales	0.00	13.95	4.96	6.45	6.70	—	—	—	(0.74)	—
	EV/FCF	(1.29)	(1.22)	(0.79)	(3.41)	(2.95)	—	—	—	(1.62)	—
Cash, $m
Cash, $m	Operating cash flow	(8)	(6)	(11)	(8)	(7)	(11)	(10)	(10)	9	(10)
	Capex	0	0	0	—	0	0	0	—	0	0
	Free cash flow	(8)	(7)	(11)	(8)	(7)	(11)	(10)	(10)	9	(10)
Balance, $m
Balance, $m	Working capital	(3)	(6)	5	3	0	7	4	3	24	18
	Total debt	0	0	0	0	0	0	0	—	—	—
	Net debt	(4)	(8)	(8)	(4)	(1)	(8)	(6)	(2)	(27)	(17)
	Shareholders’ equity	0	(2)	9	7	10	15	11	6	26	16
Returns, %
Returns, %	ROA	(138.72)	(109.98)	(75.64)	(58.19)	(53.99)	(77.72)	(70.00)	(80.55)	14.32	(35.68)
	ROIC	0.00	0.00	(727.17)	(156.13)	(48.66)	(132.31)	(141.35)	(215.23)	0.00	0.00
	ROE	(463.52)	1,171.64	(308.49)	(91.23)	(83.93)	(113.30)	(104.54)	(148.94)	22.56	(51.74)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PTN Palatin Technologies, Inc.	$11.6M	— (loss-making)	0.2×	−14.06% (below 0%: shrinking)	n/m	+34.21% (above 0%: growing)	100.00%	(1,469.35%)	Compare
CLRB Cellectar Biosciences, Inc.	$11.2M	— (loss-making)	—	−73.23% (below 0%: shrinking)	n/m	−17.49% (below 0%: shrinking)	0.00%	0.00%	Compare
INTS Intensity Therapeutics Inc.	$11.0M	— (loss-making)	—	—	n/m	+4.72% (above 0%: growing)	0.00%	0.00%	Compare
PHIO Phio Pharmaceuticals Corp.	$10.8M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−58.67% (below 0%: shrinking)	0.00%	0.00%	Compare
TPST Tempest Therapeutics, Inc.	$10.7M	— (loss-making)	—	−71.57% (below 0%: shrinking)	n/m	+67.04% (above 0%: growing)	0.00%	0.00%	Compare
KPRX Kiora Pharmaceuticals, Inc.	$10.7M	— (loss-making)	— (loss-making)	−93.64% (below 0%: shrinking)	n/m	+50.06% (above 0%: growing)	100.00%	0.00%
GDTC CytoMed Therapeutics Limited	$10.3M	— (loss-making)	— (loss-making)	—	n/m	−27.39% (below 0%: shrinking)	0.00%	—	Compare
BLRX BioLineRx Ltd.	$10.2M	— (loss-making)	— (loss-making)	−3.29% (below 0%: shrinking)	n/m	−1,827.71% (below 0%: shrinking)	79.93%	(1,215.31%)	Compare
LTRN Lantern Pharma Inc.	$10.0M	— (loss-making)	—	—	n/m	+25.31% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$10.7M	—	—	−14.06%	—	−6.38%	0.00%	0.00%

All 614 Biotechnology stocks →

Kiora Pharmaceuticals, Inc. (KPRX) key facts

Kiora Pharmaceuticals, Inc. (KPRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million.
As of October 16, 2026, KPRX traded at $2.40, a market capitalization of $10.7 million.
Return on equity was −51.7% and debt-to-equity 0.00.
Its Altman Z-score is −3.16 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.